Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Johnson & Johnson (J&J) has secured a US label expansion for its next-generation oncology combination, Akeega, in breast ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors MEDLINE (1966-2018), Embase (1982-2018), ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...